Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Current Deferred Revenue: 2017-2020

Historic Current Deferred Revenue for Cogent Biosciences (COGT) over the last 2 years, with Jun 2020 value amounting to $312,000.

  • Cogent Biosciences' Current Deferred Revenue fell 97.95% to $312,000 in Q2 2020 from the same period last year, while for Jun 2020 it was $312,000, marking a year-over-year decrease of 97.95%. This contributed to the annual value of $1.3 million for FY2019, which is 92.67% down from last year.
  • Cogent Biosciences' Current Deferred Revenue amounted to $312,000 in Q2 2020, which was down 62.90% from $841,000 recorded in Q1 2020.
  • In the past 5 years, Cogent Biosciences' Current Deferred Revenue registered a high of $20.4 million during Q2 2018, and its lowest value of $312,000 during Q2 2020.
  • Over the past 3 years, Cogent Biosciences' median Current Deferred Revenue value was $16.1 million (recorded in 2019), while the average stood at $12.5 million.
  • As far as peak fluctuations go, Cogent Biosciences' Current Deferred Revenue soared by 160.47% in 2018, and later plummeted by 97.95% in 2020.
  • Cogent Biosciences' Current Deferred Revenue (Quarterly) stood at $6.9 million in 2017, then soared by 160.47% to $17.9 million in 2018, then crashed by 92.67% to $1.3 million in 2019, then slumped by 97.95% to $312,000 in 2020.
  • Its Current Deferred Revenue was $312,000 in Q2 2020, compared to $841,000 in Q1 2020 and $1.3 million in Q4 2019.